NASDAQ:MBIO Mustang Bio (MBIO) Stock Price, News & Analysis $0.47 +0.00 (+0.83%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesOwnershipSEC Filings About Mustang Bio Stock (NASDAQ:MBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mustang Bio alerts:Sign Up Key Stats Today's Range$0.46▼$0.4850-Day Range$0.46▼$0.6352-Week Range$0.46▼$1.85Volume33,392 shsAverage Volume109,887 shsMarket Capitalization$3.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for cancer and rare genetic diseases. The company’s work centers on engineered immune-cell therapies designed to recognize and destroy cancer cells, as well as genetic medicines intended to address underlying disease causes. Mustang’s investigational programs have included MB-106, a CD20-targeted chimeric antigen receptor T-cell (CAR-T) therapy being developed for certain B-cell malignancies, and MB-101, an IL13Rα2-targeted CAR-T therapy being studied for glioblastoma and other solid tumors. These candidates have been evaluated in clinical studies, but they are investigational and have not been established as approved treatments. Mustang Bio was founded in 2015 and has operated as a biotechnology company affiliated with Fortress Biotech. The company has maintained research, development and manufacturing operations in the United States, including a cell- and gene-therapy manufacturing facility in Worcester, Massachusetts. Its therapies have been developed through internal research and collaborations with academic and clinical institutions.AI Generated. May Contain Errors. Read More Mustang Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreMBIO MarketRank™: Mustang Bio scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingMustang Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMustang Bio has only been the subject of 1 research reports in the past 90 days.Read more about Mustang Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMustang Bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mustang Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.80% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 2.49, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently increased by 6.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have not sold or bought any company stock.Percentage Held by Insiders4.00% of the stock of Mustang Bio is held by insiders.Percentage Held by Institutions9.95% of the stock of Mustang Bio is held by institutions.Read more about Mustang Bio's insider trading history. Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBIO Stock News HeadlinesMindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection KiosksJune 9, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment SolutionMay 14, 2026 | globenewswire.comMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of October 31st. See which stocks his AI research platform is flagging right now.October 2 at 1:00 AM | TradeSmith (Ad)IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.May 12, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication DetectionMay 12, 2026 | globenewswire.comMustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comSee More Headlines MBIO Stock Analysis - Frequently Asked Questions How have MBIO shares performed this year? Mustang Bio's stock was trading at $0.9810 at the beginning of 2026. Since then, MBIO shares have decreased by 52.0% and is now trading at $0.4711. How were Mustang Bio's earnings last quarter? Mustang Bio, Inc. (NASDAQ:MBIO) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($140.00) by $139.84. When did Mustang Bio's stock split? Mustang Bio shares reverse split on the morning of Thursday, January 16th 2025.The 1-50 reverse split was announced on Tuesday, January 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Mustang Bio? Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/05/2026Today10/02/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, MBIO's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MBIO CIK1680048 Webwww.mustangbio.com Phone(781) 652-4500FaxN/AEmployees4Year Founded2015Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.23% Return on Assets-17.55% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.36Miscellaneous Outstanding Shares7,580,000Free Float7,274,000Market Cap$3.57 million OptionableNot Optionable Beta2.09 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:MBIO) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
